首页>
外国专利>
Administration of Karenitecin for the Treatment of Platinum and/or Taxane Chemotherapy-Resistant or -Refractory Advanced Ovarian Cancer
Administration of Karenitecin for the Treatment of Platinum and/or Taxane Chemotherapy-Resistant or -Refractory Advanced Ovarian Cancer
展开▼
机译:给予克雷替星治疗铂和/或紫杉烷类化疗耐药或难治性晚期卵巢癌
展开▼
页面导航
摘要
著录项
相似文献
摘要
The present invention discloses and claims methods and compositions for the treatment of subjects having advanced ovarian cancer, including platinum and/or taxane chemotherapy resistant or refractory sub-populations, with the administration to the subject having advanced ovarian cancer of the silicon-containing highly lipophilic camptothecin derivative (HLCD), Karenitecin (also known as BNP1350; cositecan; 7-[(2′-trimethylsilyl)ethyl]-20(S) camptothecin) in an amount sufficient to provide a therapeutic benefit. The administration of Karenitecin by intravenous (i.v.) and/or oral methodologies are also disclosed and claimed. Methods for the administration of Karenitecin to increase Progression Free Survival (PFS) are also disclosed and claimed herein.
展开▼